BNR | Burning Rock Biotech Limited | [NASD]
Index- P/E- EPS (ttm)-1.32 Insider Own6.04% Shs Outstand102.37M Perf Week-1.09%
Market Cap279.25M Forward P/E- EPS next Y-0.56 Insider Trans0.00% Shs Float58.88M Perf Month-12.22%
Income-137.20M PEG- EPS next Q- Inst Own58.20% Short Float / Ratio1.03% / 9.32 Perf Quarter-16.26%
Sales79.60M P/S3.51 EPS this Y-22.30% Inst Trans-1.95% Short Interest0.61M Perf Half Y19.21%
Book/sh1.60 P/B1.71 EPS next Y27.30% ROA-53.30% Target Price5.55 Perf Year14.71%
Cash/sh1.25 P/C2.18 EPS next 5Y5.10% ROE-70.10% 52W Range1.70 - 4.24 Perf YTD21.33%
Dividend- P/FCF- EPS past 5Y-38.80% ROI-84.80% 52W High-35.61% Beta-
Dividend %- Quick Ratio2.70 Sales past 5Y38.30% Gross Margin67.50% 52W Low60.59% ATR0.16
Employees1138 Current Ratio3.10 Sales Q/Q-3.50% Oper. Margin- RSI (14)44.33 Volatility7.08% 5.07%
OptionableNo Debt/Eq0.00 EPS Q/Q12.10% Profit Margin- Rel Volume0.68 Prev Close2.66
ShortableNo LT Debt/Eq0.00 EarningsMay 30 BMO Payout- Avg Volume65.28K Price2.73
Recom1.70 SMA20-4.29% SMA50-5.16% SMA200-1.85% Volume47,079 Change2.63%
Date Action Analyst Rating Change Price Target Change
Oct-15-21Resumed Cowen Outperform
Jul-07-20Initiated Cowen Outperform
May-31-23 04:36AM
May-30-23 09:40AM
May-24-23 08:42AM
Apr-27-23 01:01AM
10:43PM Loading…
Apr-20-23 10:43PM
Apr-17-23 09:59AM
Mar-30-23 08:28AM
Mar-28-23 02:08AM
Mar-19-23 08:47AM
Mar-14-23 09:44AM
Mar-07-23 03:38AM
Jan-17-23 08:37PM
Jan-16-23 08:36AM
Jan-03-23 09:25AM
09:24AM Loading…
Dec-27-22 09:10AM
Dec-15-22 06:52AM
Nov-21-22 12:00PM
Nov-15-22 09:20PM
Nov-10-22 05:15AM
Nov-01-22 06:10AM
Oct-27-22 07:50AM
Oct-25-22 12:46AM
Oct-21-22 01:01PM
Oct-10-22 06:25AM
Sep-08-22 04:56AM
Aug-31-22 04:30PM
05:29AM Loading…
Aug-09-22 07:46AM
Aug-04-22 09:10AM
Aug-03-22 02:12AM
Jul-14-22 09:50PM
Jul-08-22 06:49AM
Jun-30-22 10:57AM
Jun-24-22 03:26AM
Jun-21-22 02:03AM
Jun-15-22 08:01AM
Jun-01-22 07:49AM
May-31-22 01:30PM
May-16-22 04:00AM
May-05-22 06:45PM
May-02-22 11:43AM
Mar-31-22 05:46AM
Mar-22-22 04:30PM
Mar-21-22 08:30PM
Mar-16-22 06:54PM
Mar-15-22 09:38AM
Mar-02-22 10:29AM
Feb-21-22 11:30PM
Jan-17-22 03:38PM
Dec-28-21 08:05PM
Dec-27-21 10:00PM
Dec-10-21 06:38PM
Nov-17-21 08:15PM
Nov-15-21 10:21PM
Nov-04-21 03:06AM
Nov-03-21 12:00AM
Aug-31-21 12:00PM
Aug-03-21 03:00AM
Aug-02-21 04:00AM
Jul-26-21 02:15AM
Jun-11-21 06:49AM
May-26-21 04:00AM
May-25-21 06:15AM
May-19-21 05:06AM
May-12-21 04:00AM
Apr-29-21 07:30AM
Apr-28-21 10:00PM
Apr-20-21 07:21AM
Apr-13-21 03:39AM
Mar-19-21 02:21PM
Mar-14-21 04:09AM
Mar-11-21 05:15AM
Mar-10-21 07:00PM
Feb-08-21 08:00PM
Jan-22-21 08:30AM
Dec-15-20 08:18AM
Dec-11-20 02:21PM
Dec-04-20 06:34AM
Dec-01-20 06:47PM
Nov-20-20 06:15AM
Nov-15-20 08:00PM
Oct-29-20 11:21PM
Oct-20-20 09:30PM
Burning Rock Biotech Limited primarily develops and commercializes cancer therapy selection tests in the People's Republic of China. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company primarily offers next-generation sequencing-based tissue and liquid biopsy cancer therapy selection and prognosis prediction tests for various range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples. Its principal products include OncoCompass IO, a corresponding test for liquid biopsy samples; OncoScreen IO, a pan-cancer test for tissue samples; and OncoCompass Target, a ctDNA liquid biopsy-based test for NSCLC. In addition, the company provides ColonCore for assessing microsatellite loci related to MSI status and detecting mutations in genes associated with gastrointestinal cancers; and brPROPHET, a pre-operative ctDNA detection and post-operative MRD calling for relapsed patients. Further, it has development and commercialization agreement with Myriad Genetics, Inc. to in-license Myriad myChoice tumor testing in China; licensing agreement with Oncocyte Corporation to in-license DetermaRx, a risk stratification test for early stage lung cancer patients in China; and collaborations on clinical trials and research studies with AstraZeneca, Bayer, Johnson & Johnson, CStone, BeiGene, Abbisko Therapeutics, and IMPACT Therapeutics and Merck KGaA. Additionally, the company offers OncoMaster, an automatic NGS data analysis and report interpretation machine for in-hospital model. Burning Rock Biotech Limited was incorporated in 2014 and is headquartered in Guangzhou, China.